The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways

BJU International

Volumn 95, Issue 9, 2005, Pages 1327-1335

  Edwards, Joanne ^a   Bartlett, John M S ^a  

^a University Department of Surgery   (United Kingdom)

Author keywords

Androgen receptor; Hormone resistance; IL 6R; JAK and STAT3; MAP kinase; PI3K; SRC 1

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT3 PROTEIN; STEROID RECEPTOR COACTIVATOR 1;

CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; GENE AMPLIFICATION; GENE MUTATION; HORMONE RESISTANCE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HISTONE ACETYLTRANSFERASES; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NUCLEAR RECEPTOR COACTIVATOR 2; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 20444368837     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05527.x     Document Type: Review

References (47)

1. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocrine-Related Cancer 2002; 9: 61-73
2. Ueda T, Max DT, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002; 277: 38087-94
3. Lee HJ, Chang C. Recent advances in androgen receptor action. Cellular Mol Life Sci 2003; 60: 1613-22
4. Gelfanov VM, Burgess GS, Litz-Jackson S et al. Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappa B-mediated antiapoptosis involving c-IAP2. Blood 2001; 98: 2508-17
5. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996; 93: 5517-21
6. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocrine-Related Cancer 2002; 9: 155-70
7. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308
8. Wang X, Yang Y, Quo X et al. Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 2002; 277: 15426-31
9. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998; 95: 7379-84
10. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 11083-8
11. Gao T, Brantley K, Bolu E, McPhaul MJ. RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol 1999; 13: 1645-56
12. Alen P, Claessens F, Schoenmakers E et al. Interaction of the putative androgen receptor-specific coactivator ARA70/ ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. Mol Endocrinol 1999; 13: 117-28
13. Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL. Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocrine-Related Cancer 2004; 11: 117-30
14. Wise SC, Burmeister LA, Zhou XF et al. Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene 1998; 16: 2001-9
15. Rochette-Egly C. Nuclear receptors. integration of multiple signalling pathways through phosphorylation. Cellular Signalling 2003; 15: 355-66
16. Bubulya A, Chen SY, Fisher G, Zheng Z, Shen XQ, Shemshedini L. c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. J Biol Chem 2001; 276: 44704-11
17. Linja MJ, Porkka KP, Kang ZK et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10: 1032-40
18. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocrine-Related Cancer 2003; 10: 209-16
19. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MARK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-85
20. Louie MC, Yang HQ, Ma AH et al. Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci USA 2003; 100: 2226-30
21. Halkidou K, Gnanapragasam VJ, Mehta PB et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003; 22: 2466-77
22. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002; 277: 25904-13
23. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen dA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003; 63: 7638-40
24. Huang ZQ, Li JW, Wong JM. AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 2002; 16: 924-37
25. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-6
26. Mora LB, Buettner R, Seigne J et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-66
27. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2002; 60: 2132-5
28. Trachtenberg J, Blackledge G. Looking to the future. Advances in the management of hormone-refractory prostate cancer. Eur Urol Suppl 2002; 1: 44-53
29. Corcoran NM, Costello AJ. Interleukin-6. Minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91: 545-53
30. Sanford DC, Dewille JW. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate 2004; 63: 143-54
31. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000; 42: 88-98
32. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63: 1981-9
33. Bell WC, Myers RB, Hosein TO, Oelschlager DK, Grizzle WE. The response of extracellular signal-regulated kinase (ERK) to androgen-induced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotechnic Histochem 2003; 78: 11-6
34. Fu Z, Smith PC, Zhang LZ et al. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003; 95: 878-89
35. Edwards J, Krishna NS, Witton CJ, Bartlett JMS. Gene Amplifications Associated with the Development of hormone resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-81
36. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cellular Biochem 2004; 91: 13-25
37. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84
38. Edwards J, Krishna NS, Mukherjee R, Bartlett JMS. The role of c-Jun and c-Fos expression in Androgen Independent Prostate Cancer. J Pathol 2004; 204: 153-8
39. Sato N, Sadar MD, Bruchovsky N et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997; 272: 17485-94
40. Bonaccorsi L, Muratori M, Carloni V et al. Androgen receptor and prostate cancer invasion. Int J Androl 2003; 26: 21-5
41. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer; Molecular biology of early progression to androgen independence. Endocrine-Related Cancer 1999; 6: 487-502
42. Sadar MD. Androgen independent induction of prostate specific antigen gene expression via cross talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999; 274: 7777-83
43. Sun M, Yang L, Feldman RI et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85 alpha, androgen receptor, and Src. J Biol Chem 2003; 278: 42992-3000
44. Gao N, Zhang Z, Jiang BH, Shi XL. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Comms 2003; 310: 1124-32
45. Li PF, Lee H, Quo SD, Unterman TG, Jenster G, Bai WL. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cellular Biol 2003; 23: 104-18
46. Iahn M, Sundel K, Cleave M et al. Protein kinase C-alpha in prostate cancer. BJU Int 2004; 93: 1076-81
47. Mackay HJ, Twelves CJ. Protein kinase C. A target for anticancer drugs? Endocrine-Related Cancer 2003; 10: 389-96